Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials